Boothbay Fund Management’s BriaCell Therapeutics Warrant expiring 2031 BCTXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-20,000
Closed -$83.8K – 2757
2026
Q1
$83.8K Buy
+20,000
New +$21.2K ﹤0.01% 1888

Other funds holding BCTXL

Boothbay Fund Management's BCTXL Position: Q2 2026 in Review

Boothbay Fund Management sold out of BriaCell Therapeutics Warrant expiring 2031 (BCTXL) in Q2 2026, closing a stake of 20,000 shares — an estimated $83.8K sold.

Boothbay Fund Management first reported a position in BCTXL in Q1 2026 and held it in 1 quarter. The position peaked at $83.8K in Q1 2026. 10 funds tracked by Wall St. Rank hold BCTXL as of Q2 2026.

  • Boothbay Fund Management reported no remaining BriaCell Therapeutics Warrant expiring 2031 position as of Q2 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 20,000 BriaCell Therapeutics Warrant expiring 2031 shares in Q2 2026, an estimated $83.8K.
  • Boothbay Fund Management first reported a position in BriaCell Therapeutics Warrant expiring 2031 in Q1 2026 and held it in 1 quarter.
  • Boothbay Fund Management's BriaCell Therapeutics Warrant expiring 2031 position peaked at $83.8K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant expiring 2031 as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.